On June 29th, the 9th China BioMed Innovation and Cooperation Conference and the 2023 China BioMed Industry Value List Awards Ceremony officially opened in Suzhou. The list of winners was announced at the event, and Hopstem's strength in the field of biotechnology was once again recognized by the industry, ranking in the top 10 most promising biotech companies.

This ranking reflects the industry's high recognition of Hopstem's innovative iPSC-derived cell therapy platform. In the future, we will continue to adhere to the concept of "Unlimited Innovation to change life", continuously develop and promote the company's clinical pipeline, and benefit patients as soon as possible.